Albumin
Albumins unique properties offer unlimited potential in the field of medical science.
Learn morePRESS RELEASE: Valneva’s inactivated COVID-19 vaccine, VLA2001, including Albumedix´ Recombinant Human Albumin (rHA) as an essential component, received regulatory approval from MHRA on April 14th. This marks an expansion of the companies’ existing collaboration and further validates the use of Albumedix Recombumin® rHA products in the manufacturing process and final formulation of critical vaccines.
Read moreHas COVID-19 revolutionizedthe future of regulation of medicine development and authorization or are we simply responding to an unprecedented global pandemic? Our Head of Regulatory Affairs and Enhanced Services, Harriet Edwards, delves deep on how the pademic changed the industry we work in today.
Read morePRESS RELEASE: Nottingham, UK, 1 September 2021 – Albumedix Ltd. (‘Albumedix’), a globally recognized leader in albumin-based enabling solutions for advanced therapies and next-generation biopharmaceuticals, announced today the appointment of Joanna Hay as Vice President of Commercial Operations, effective as of September 1st, 2021.
Read moreSurface engineering is key for medical devices, particularly the ones that interact with the human body like tubing, catheters, and stents which need to be implanted. It is essential to have strong control on the performance of the coatings, so that everyone is assured that they are uniformly present on the surfaces, that the coatings allow an effective flow of body fluids (such as blood), and that they promote a long lifespan not diminishing or reducing the effectiveness of the medical device in use1 - all of the above, according to the regulation standards, are required to be met by oversight groups.
Read morePRESS RELEASE: Nottingham, UK, 2nd August 2021 – Albumedix Ltd. (‘Albumedix’), a globally recognized leader in albumin-based enabling solutions for advanced therapies and next-generation biopharmaceuticals, announced today the appointment of Mark Kalinowski as Chief Financial Officer, effective as of August 2nd, 2021.
Read moreThe BIO Digital 2021 convention attracted thousands of biotech leaders and innovators from around the world with the objective to transform the future of science.
Read moreThe treatment or prevention of a disease through the administration of cells that have been selected, manipulated, or altered outside of the body, is defined as cell therapy.
Read moreWe virtually sent our European Business Development Director Joanna Hay, as well as Business Development Associates Edward Thornton and Maciej Trybull to catch up with current and future partners in the Advanced Therapy Medicinal Product (ATMP) community and listen in on the exciting talks setting the direction of the industry.
Read moreCollaboration investigates enhanced manufacturing of AAV and lentiviral vectors to improve quality and productivity for gene therapy and vaccine developers
Read moreAlbumedix Ltd., a recognized global leader in recombinant human albumin specializing in the enablement of advanced therapies, announces the completed expansion of the company’s commercial-scale manufacturing facility, alongside with the establishment of a new Technology Centre equipped with state-of-the-art laboratories at its UK-based campus in Nottingham.
Read moreDid you know that unlike other recombinant human albumin manufacturers, Albumedix are so much more than simply ‘an albumin supplier’? When you work with us, you also get access to 100 brilliant minds behind the vial, including a dedicated Business Development Director responsible for managing your account.
Read moreMeet Dangerous Dave Phillipson; a formidable, Nottingham based, three-time Paralympian in tennis who took to the water in 2017 and is now paracanoeing his way to Tokyo 2021.
Read moreMeet Helen Rawsthorne. Helen is a Senior Research Scientist within Albumedix and a truly brilliant example of our many brilliant minds. Presently in her 7th year working for the company, the following interview will take you through Helen's background, her role within Albumedix and give you a sneak preview into what our Technical Group get up to in the day.
Read moreAlbumedix are thrilled to be able to continue supporting the Nottinghamshire Wildlife Trust in their endeavours to protect and restore the beautiful environment and wildlife both on our doorstep and across the region.
Read moreAlbumedix is a world leading manufacturer of recombinant human albumin (rHA), and as such our manufacturing plant is the core of our business. As a company, we talk a lot about our rHA products, how they’re useful in different applications and what benefits they can bring to final therapies for patients worldwide. However, we don’t talk as much about the amazing people within our business that make the magic happen.
Read moreIn December, Albumedix held a 'Capping off Ceremony' to celebrate the brand new, four-storey manufacturing plant extension being confirmed as watertight!
Read moreAlbumedix Ltd is now a part of Sartorius. This form links to Sartorius.com and will allow our integrated sales team to get in touch to support the fulfilment of a new order, evaluation or, indeed, to answer any of your product or service questions. Any data provided will be available to Sartorius and its affiliates.
Please check the Sartorius privacy notice using the link provided to see how your data is being processed: https://www.sartorius.com/en/privacy-notices